Aclaris Therapeutics Inc (ACRS) - News Archive

Aclaris Therapeutics: Strategic Inducement Grants Amid Promising Clinical AdvancesOn September 17, 2024, Aclaris Therapeutics Inc. announced the initiation of dual Phase 2a clinical trials for ATI-2138, aiming to addres...

Aclaris Therapeutics has recently completed a pivotal step in the journey of ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor, by dosing the first patient in not one, but two Phase 2a clinical trials. These...

Aclaris Therapeutics, a prominent player in the healthcare sector, has recently announced significant leadership changes and a strategic business review. The decision comes after a period of financial underperformance,...

: Aclaris Therapeutics recently announced positive top-line results from their four-week Phase 2b trial of ATI-1777, an investigational topical soft Janus kinase (JAK) inhibitor, in patients with mild to severe atopic d...

In a pivotal corporate update, Aclaris Therapeutics Inc., a pharmaceutical company specializing in dermatological treatments, provided significant insights into their ongoing efforts and the systemic changes anticipated...

Aclaris Therapeutics Partners with Sun Pharma in Patent License Agreement for AlopeciaIn a significant move towards revolutionizing treatment options for alopecia, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a leading cl...